|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
2010-9-17
|
|
pubmed:abstractText |
Glioblastoma multiforme (GBM) is refractory to conventional therapies. To overcome the problem of heterogeneity, more brain tumor markers are required for prognosis and targeted therapy. We have identified and validated a promising molecular therapeutic target that is expressed by GBM: human multidrug-resistance protein 3 (MRP3).
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1471-2407
|
|
pubmed:author |
pubmed-author:BignerDarell DDD,
pubmed-author:HerndonJames EJE2nd,
pubmed-author:KuanChien-TsunCT,
pubmed-author:LippEric SES,
pubmed-author:McLendonRoger ERE,
pubmed-author:PegramCharles NCN,
pubmed-author:RasheedAhmedA,
pubmed-author:RigginsGregory JGJ,
pubmed-author:SzafranskiScott ESE,
pubmed-author:WakiyaKenjiK,
pubmed-author:WikstrandCarol JCJ
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
468
|
|
pubmed:dateRevised |
2011-2-9
|
|
pubmed:meshHeading |
pubmed-meshheading:20809959-Animals,
pubmed-meshheading:20809959-Antibodies, Monoclonal,
pubmed-meshheading:20809959-Blotting, Western,
pubmed-meshheading:20809959-Brain,
pubmed-meshheading:20809959-Brain Neoplasms,
pubmed-meshheading:20809959-Case-Control Studies,
pubmed-meshheading:20809959-Cells, Cultured,
pubmed-meshheading:20809959-Female,
pubmed-meshheading:20809959-Glioblastoma,
pubmed-meshheading:20809959-Humans,
pubmed-meshheading:20809959-Immunoenzyme Techniques,
pubmed-meshheading:20809959-Immunotherapy,
pubmed-meshheading:20809959-Male,
pubmed-meshheading:20809959-Mice,
pubmed-meshheading:20809959-Mice, Inbred BALB C,
pubmed-meshheading:20809959-Middle Aged,
pubmed-meshheading:20809959-Multidrug Resistance-Associated Proteins,
pubmed-meshheading:20809959-Neoplasm Staging,
pubmed-meshheading:20809959-Prognosis,
pubmed-meshheading:20809959-RNA, Messenger,
pubmed-meshheading:20809959-Rabbits,
pubmed-meshheading:20809959-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:20809959-Survival Rate,
pubmed-meshheading:20809959-Tumor Cells, Cultured,
pubmed-meshheading:20809959-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
MRP3: a molecular target for human glioblastoma multiforme immunotherapy.
|
|
pubmed:affiliation |
Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA. kuan@duke.edu
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
